Dr. Roman Bartz, Head & Director Clinical Affairs of Therawis Pharma, has more than fifteen years of professional experience in clinical development especially in oncology. Between 2001 and 2014 Dr. Bartz was responsible at Wilex AG, an oncology focused biotech company, for clinical development of the antibody-based diagnostic imaging agent in renal cell carcinoma, including successful performance of a pivotal Phase III trial and for early clinical oncology trials of the small molecule program. In addition, he gained significant experience through interactions with regulatory authorities (FDA: pre-IND, IND, SPA, ODAC-meeetings and the EMA: Scientific Advise-meetings). Dr. Bartz was also in charge of Investigator Initiated Trials and organizing and supervising scientific advisory meetings and expert Meetings. From 1998-2001, he served as a lead-CRA for Kendle, a renowned international CRO in the Munich offices, where he was engaged in the conduct of several national and international clinical trials in various indications. From 1994 to 1998 Dr. Bartz worked at the Julius-Maximilians University of Würzburg, where he also earned his PhD at the Institute of Virology and Immunology.